{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:41:03Z","timestamp":1761864063836,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011928","name":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.annonc.2019.12.009","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T02:16:05Z","timestamp":1579140965000},"page":"495-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)"],"prefix":"10.1016","volume":"31","author":[{"given":"Y.","family":"Metaxas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.I.","family":"Eboulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.L.","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Perrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Biaggi-Rudolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2019.12.009_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2019.12.009_bib2","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib3","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/ejcts\/ezv398","article-title":"Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma","volume":"49","author":"Kostron","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2019.12.009_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ctrv.2015.10.006","article-title":"Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma","volume":"41","author":"Ceresoli","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2019.12.009_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2019.12.009_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/sonc.2002.30232","article-title":"The role of gemcitabine in the treatment of malignant mesothelioma","volume":"29","author":"Kindler","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: a systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2019.12.009_bib9","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2019.12.009_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib12","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thor Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"issue":"15 suppl","key":"10.1016\/j.annonc.2019.12.009_bib15","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/jco.2014.32.15_suppl.5505","article-title":"Lurbinectedin (PM01183), an active compound in platinum-resistant\/refractory ovarian cancer (PROC) patients: results of a two-stage, controlled phase II study","volume":"32","author":"Poveda","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2019.12.009_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0197-2456(98)00012-9","article-title":"A design alternative for two-stage, phase II, multicenter cancer clinical trials","volume":"19","author":"Herndon","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.annonc.2019.12.009_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A\u00a0systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Resp Med"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2019.12.009_bib19","first-page":"v851","article-title":"A\u00a0multicenter randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma (MPM) \u2013 results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/JTO.0b013e31815608d9","article-title":"Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center","volume":"2","author":"Flores","year":"2007","journal-title":"J\u00a0Thor Oncol"},{"issue":"suppl 8","key":"10.1016\/j.annonc.2019.12.009_bib22","doi-asserted-by":"crossref","first-page":"viii332","DOI":"10.1093\/annonc\/mdy285","article-title":"Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: results of CORAIL trial","volume":"29","author":"Gaillard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.12.009_bib23","first-page":"458","article-title":"Living with mesothelioma. A literature review","volume":"19","author":"Moore","year":"2010","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.annonc.2019.12.009_bib24","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.ejca.2015.08.004","article-title":"Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome","volume":"51","author":"Monzon","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420359263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420359263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:56:45Z","timestamp":1760335005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420359263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0923753420359263"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2019.12.009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2019.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}